Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.

Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development

A Focus on Early Phase Clinical Studies - Previously published in hardcover
BuchKartoniert, Paperback
312 Seiten
Englisch
Springererschienen am22.09.2016Softcover reprint of the original 1st ed. 2015
This book reviews techniques for assessing insulin action, insulin secretion and body composition, with reference to new drugs, in phase 1 & 2 studies. Adds to understanding of drug effects and non-drug treatment strategies in obesity and type 2 diabetes.mehr

Produkt

KlappentextThis book reviews techniques for assessing insulin action, insulin secretion and body composition, with reference to new drugs, in phase 1 & 2 studies. Adds to understanding of drug effects and non-drug treatment strategies in obesity and type 2 diabetes.
Details
ISBN/GTIN978-1-4471-7032-7
ProduktartBuch
EinbandartKartoniert, Paperback
Verlag
Erscheinungsjahr2016
Erscheinungsdatum22.09.2016
AuflageSoftcover reprint of the original 1st ed. 2015
Seiten312 Seiten
SpracheEnglisch
Gewicht612 g
IllustrationenXII, 312 p. 76 illus., 39 illus. in color.
Artikel-Nr.15664774
Rubriken
GenreMedizin

Inhalt/Kritik

Inhaltsverzeichnis
1. Review of physiology/pathophysiology.- 2. Methods for assessing insulin action in humans.- 3. Assessment of insulin secretion.- 4. Measurement of ectopic fat in liver and muscle using magnetic resonance spectroscopy.- 5. Isotopic tracers for the measurement of metabolic flux.- 6. Measuring food intake in clinical drug development.- 7. Measurement of energy expenditure.- 8. Assessment of body composition.- 9.  Assessment of cardiovascular safety of new diabetes drugs.mehr
Kritik
"An important resource for researchers to orient themselves in the choice of correct study techniques, for both metabolic studies related to drug development and clinical studies. ... it is also a great resource for experienced researchers in the field as a useful compendium of the major and emerging techniques already used in the study of the pathophysiology of metabolism, and as a valuable aid to researchers beginning studies in the field for choosing the most appropriate techniques for their purposes." (Stefania Camastra, Pharmaceutical Medicine, Vol. 30, 2016)mehr

Autor

Andrew J Krentz, Senior Director of Scientific Services at the Profil Institute, is a clinical academic with more than three decades of experience in diabetes and cardiometabolic medicine. He holds a visiting chair at the Bedfordshire & Hertfordshire Postgraduate Medical School, University of Bedfordshire UK where he was Associate Professor before joining Profil. Prior to this he was a senior physician in internal medicine, diabetes & endocrinology at Southampton University Hospitals, UK. Lutz Heinemann, Senior Scientific Consultant at the Profil Institute, has acted as scientific advisor for Profil Institute since the company´s inception in 2004. He consults on the design of clinical trial protocols and in the publication of study results. He is also co-founder of Profil Institute for Metabolic Research in Neuss, Germany and led the company as CEO for 10 years until 2009. Prior to that, Prof. Dr. Heinemann spent 17 years performing diabetes-related clinical and experimental research at the Department of Metabolic Diseases and Nutrition, a World Health Organization Collaborating Center of Diabetes, at Heinrich-Heine University of Düsseldorf in Germany. Marcus Hompesch, President and Chief Executive Officer, Profil Institute, is an expert in the field of metabolic diseases, a licensed physician and entrepreneur. His experience in designing, performing and publishing clinical studies in metabolic diseases has been gained through over 18 years of work as clinician and clinical researcher. Dr. Hompesch established Profil Institute for Clinical Research in San Diego, CA in 2003.